Recording Date: May 14th, 2020
Presenter: Dr. Houda Hachad, Chief Science Officer Translational Software

Summary of Webinar

Malignant hyperthermia (MH) is a rare life-threatening condition that may occur during surgical procedures. The condition is recognized as an inherited pharmacogenetic syndrome that can be triggered by commonly used volatile anesthetic agents and/or succinylcholine. In this webinar, Dr Houda Hachad will do an overview of the CPIC-guideline for the use of triggering agents in the context of RYR1 or CACNA1S genotypes and share best practices for proper implementation. She will discuss the benefits of genetic testing for variants that confer MH susceptibility, result interpretation and the role of genetic counseling.


About the Presenter

Houda-HachadHouda is an entrepreneurial scientist with deep experience in pharmacology and pharmacogenetics. At the University of Washington, she co-developed two knowledge-based technologies, a drug interaction database (DIDB) and a pharmacogenetics database (e-PKGene©). Both leverage revenue-based funding and are widely used by pharmaceutical companies, regulatory agencies, and academic institutions worldwide.